Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2689 of 3330
Next
>>
>
67201 to 67225 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7540.068	0.4275	-0.1688	0.9679
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7540.068	0.0983	-0.8179	0.9679
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	167	uM	7540.068	0.0190	-0.9666	0.9679
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0000853	uM	7541.069	0.9754	0.9675	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	7541.069	0.8519	0.7998	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7541.069	0.7057	0.5901	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7541.069	0.5066	0.2785	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7541.069	0.4569	0.1945	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7541.069	0.4648	0.2080	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	7541.069	0.4686	0.2146	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7541.069	0.4133	0.1183	1.5197
SUM52PE	HR+	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7541.069	0.1471	-0.4334	1.5197
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0000853	uM	7543.069	0.9723	0.9612	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	7543.069	0.9184	0.8848	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	7543.069	0.8709	0.8163	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	7543.069	0.7766	0.6767	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	7543.069	0.7037	0.5654	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.267	uM	7543.069	0.6755	0.5213	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	1.33	uM	7543.069	0.6382	0.4622	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	6.67	uM	7543.069	0.6021	0.4040	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	33.3	uM	7543.069	0.4339	0.1173	1.4340
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.000427	uM	9033.068	0.9887	0.9766	0.9662
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.00213	uM	9033.068	0.9519	0.9005	0.9662
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0107	uM	9033.068	0.8281	0.6453	0.9662
T47D	HR+	Luminal	Sirolimus	MTOR	MTOR	0.0533	uM	9033.068	0.7725	0.5311	0.9662

|<
<<
Previous
Page 2689 of 3330
Next
>>
>
67201 to 67225 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)